ImpediMed

ImpediMed LT Debt/Equity

The Long-Term Debt to Equity Ratio of ImpediMed (IPD.AX) as of Nov 11, 2026 is 1.58. In the previous year, Long-Term Debt to Equity Ratio was 0.69 — a change of 127.53% (higher).

LT Debt/Equity

1.58

YoY

127.53%

Last updated:

Long-Term Debt to Equity Ratio of ImpediMed is 2026 1.58 . Long-Term Debt to Equity Ratio of ImpediMed was 2025 0.69 . It decreases by 127.53% higher compared to the previous year.

The ImpediMed LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2019
0.00 AUD
Jan 1, 2020
0.02 AUD
Jan 1, 2021
0.01 AUD
Jan 1, 2022
0.00 AUD
Jan 1, 2023
0.02 AUD
Jan 1, 2024
0.02 AUD
Jan 1, 2025
0.69 AUD
Jan 1, 2026
1.58 AUD
The ImpediMed LT Debt/Equity history
YEARLT Debt/EquityYoY
1.58+127.53%
0.69+3,391.01%
0.02+5.52%
0.02—
0.00-100.00%
0.01-66.37%
0.02—
0.00—
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

Long-Term Debt to Equity Ratio of ImpediMed is 1.58 in 2026.

Long-Term Debt to Equity Ratio of ImpediMed changed from 0.69 to 1.58, representing a 127.53% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio ImpediMed since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's ImpediMed with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — ImpediMed

All Key Metrics — ImpediMed